Ankasa Regenerative Therapeutics

Ankasa Regenerative Therapeutics is a private, San Diego-based biotech founded in 2015, focused on harnessing the Wnt signaling pathway for regenerative medicine. The company has developed a proprietary platform to produce human Wnt proteins for therapeutic use, with its lead candidate, ART352-L, in development to improve outcomes in spinal fusion and other bone reconstructive procedures. Ankasa is pre-revenue and in the pre-clinical/IND-enabling stage, backed by over $25M in venture capital and non-dilutive grant funding from investors like Avalon Ventures and CIRM. Its strategy targets a significant unmet need in bone healing, aiming to reduce revision surgeries and associated healthcare costs.

Proprietary platform for manufacturing bioactive, human Wnt proteins suitable for human therapeutic use, designed to activate endogenous stem cells for tissue regeneration.

Ankasa competes in the bone graft and orthopedic biomaterials market against established products like bone morphogenetic proteins (BMPs, e.g., Medtronic's Infuse), allografts, and synthetic bone substitutes. Its differentiation lies in its novel mechanism (Wnt pathway activation) and localized, stem-cell-targeting approach, which aims for more controlled and potent bone formation with potentially fewer side effects than high-dose BMPs.